IMCR Immunocore Holdings plc Stock Quote

IMCR [NASD]

Healthcare | Biotechnology | United Kingdom

Index	-	P/E	-	EPS (ttm)	-3.85	Insider Own	22.54%	Shs Outstand	43.86M	Perf Week	-1.51%
Market Cap	1.22B	Forward P/E	-	EPS next Y	-243.01	Insider Trans	0.00%	Shs Float	33.01M	Perf Month	-15.28%
Income	-163.90M	PEG	-	EPS next Q	-65.49	Inst Own	46.00%	Short Float	3.47%	Perf Quarter	26.36%
Sales	33.00M	P/S	37.06	EPS this Y	-76.70%	Inst Trans	11.66%	Short Ratio	5.92	Perf Half Y	-21.60%
Book/sh	4.87	P/B	5.90	EPS next Y	0.50%	ROA	-38.50%	Target Price	53.50	Perf Year	-26.01%
Cash/sh	6.96	P/C	4.13	EPS next 5Y	-	ROE	-62.50%	52W Range	18.43 - 42.25	Perf YTD	-16.15%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-53.40%	52W High	-32.05%	Beta	-
Dividend %	-	Quick Ratio	4.30	Sales past 5Y	-	Gross Margin	-	52W Low	55.78%	ATR	2.15
Employees	324	Current Ratio	4.30	Sales Q/Q	-10.80%	Oper. Margin	-	RSI (14)	42.87	Volatility	5.67% 7.80%
Optionable	Yes	Debt/Eq	0.37	EPS Q/Q	-101.20%	Profit Margin	-	Rel Volume	1.17	Prev Close	29.53
Shortable	Yes	LT Debt/Eq	0.36	Earnings	-	Payout	-	Avg Volume	193.46K	Price	28.71
Recom	1.70	SMA20	-6.49%	SMA50	-8.89%	SMA200	-8.85%	Volume	226,065	Change	-2.78%

Feb-08-22

Initiated

H.C. Wainwright

Buy

$80

Oct-20-21

Initiated

Oppenheimer

Outperform

$56

Mar-02-21

Initiated

JP Morgan

Overweight

$58

Mar-02-21

Initiated

Jefferies

Buy

$65

Mar-02-21

Initiated

Goldman

Neutral

$40

May-23-22 07:24AM	Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand PR Newswire
07:24AM	Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand CNW Group
May-21-22 08:00AM	These Analysts Just Made A Significant Downgrade To Their Immunocore Holdings plc (NASDAQ:IMCR) EPS Forecasts Simply Wall St.
May-11-22 07:00AM	Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update GlobeNewswire -12.24%
May-03-22 09:28AM	Could The Immunocore Holdings plc (NASDAQ:IMCR) Ownership Structure Tell Us Something Useful? Simply Wall St.
May-02-22 10:45AM	Novartis Is Looking for Deals. Are These 3 Biotechs on Its List? Motley Fool +5.49%
Apr-07-22 07:00AM	Immunocore to present at the 21st Annual Needham Healthcare Conference GlobeNewswire
Apr-06-22 07:01AM	2 Biotechs With Recent FDA Approvals to Hold for the Next Decade Motley Fool
Apr-04-22 11:05AM	Immunocore Eye Cancer Cell Therapy Scores European Approval Benzinga +10.63%
07:00AM	European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma GlobeNewswire
Apr-01-22 09:00PM	3 CEOs to Invest In Motley Fool
01:20PM	Immunocore Holdings (NASDAQ:IMCR) shareholders are up 5.3% this past week, but still in the red over the last year Simply Wall St.
Mar-16-22 12:00PM	Immunocore Holdings PLC Sponsored ADR (IMCR) Moves to Buy: Rationale Behind the Upgrade Zacks +8.95%
10:00AM	Wall Street Analysts See a 135% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High? Zacks
Mar-09-22 05:30PM	Immunocore to present at Oppenheimers 32nd Annual Healthcare Conference GlobeNewswire +5.98%
Mar-03-22 07:00AM	Immunocore Reports Full Year 2021 Financial Results and Provides Business Update GlobeNewswire
Feb-25-22 02:00AM	Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma GlobeNewswire
Feb-11-22 07:00AM	Immunocore to present at the SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-26-22 12:15PM	Immunocore gets FDA approval for cell therapy targeting melanoma American City Business Journals +7.52%
09:11AM	FDA Approves First T Cell Receptor Therapy From Immunocore For Eye Cancer Benzinga
07:00AM	Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma GlobeNewswire
Jan-06-22 07:00AM	Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-06-21 07:00AM	Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4 GlobeNewswire
Nov-11-21 07:00AM	Immunocore to present at the Jefferies London Healthcare Conference GlobeNewswire
Nov-10-21 07:00AM	Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Nov-09-21 08:01AM	Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting GlobeNewswire
Nov-01-21 09:07AM	What Kind Of Shareholders Hold The Majority In Immunocore Holdings plc's (NASDAQ:IMCR) Shares? Simply Wall St.
Oct-18-21 07:30AM	Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel GlobeNewswire
Sep-22-21 06:00PM	Immunocore announces publication of phase 3 data comparing tebentafusp with investigators choice in The New England Journal of Medicine GlobeNewswire
Sep-20-21 07:00AM	Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial GlobeNewswire
Sep-13-21 04:30PM	Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 GlobeNewswire
Sep-10-21 07:00AM	Immunocore to present at upcoming investor conferences GlobeNewswire
Sep-08-21 07:00AM	Immunocore Announces UKs Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma GlobeNewswire
Aug-24-21 07:00AM	Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma GlobeNewswire +8.40%
Aug-11-21 07:00AM	Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Jul-27-21 07:00PM	Is Immunocore Holdings plc (IMCR) A Good Stock To Buy? Insider Monkey
Jun-04-21 09:05AM	Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-28-21 08:06PM	Genesco, Immunocore See Activist Action Barrons.com
May-27-21 04:30PM	Immunocore to present at upcoming investor conferences GlobeNewswire
May-18-21 04:10PM	Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B GlobeNewswire
May-12-21 07:00AM	Immunocore Reports First Quarter 2021 Financial Results GlobeNewswire
May-05-21 07:42AM	What You Need To Know About Immunocore Holdings plc's (NASDAQ:IMCR) Investor Composition Simply Wall St.
Apr-28-21 04:30PM	Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-22-21 05:52AM	3 Recent IPO Stocks That Could Be Bigger Winners Than Coinbase Motley Fool
Apr-12-21 04:30PM	Immunocore presents phase 3 data comparing tebentafusp with investigators choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting GlobeNewswire -9.16%
Mar-25-21 07:00AM	Immunocore Provides Business Update and Reports Full Year 2020 Financial Results GlobeNewswire +5.98%
Mar-10-21 07:00PM	Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting GlobeNewswire
Feb-19-21 07:00AM	Immunocores tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA GlobeNewswire

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience